The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 73% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
Absci Corporation
ABSI · Nasdaq · USD · Market cap $1.6B · 140 employees
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
FAIL · Does not pass the screenPrice as of 17 Nov 2026Daily close, not a live quote
Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price7.58 USD at the 17 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 17 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.49)
- Last reviewed17 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $10.00 to $16.90, base estimate $15.00 (screen dated 2026-11-17).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.49, read 2026-11-13
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Absci Corporation holds its Markup at $7.58. The statistical read favours the sellers, held for 28 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 28 days |
| Price at the screen | $7.58 |
| Valuation | N/A trailing · -13.54 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 2.19 |
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 2.45% | Below 33% | Interest-bearing debt is just 2.5% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 57.45% | Below 33% | Interest-bearing cash and securities are 57.5% of assets, above the one-third limit. | Fail |
| Receivables | 9.26% | Below 49% | Money owed to the company is 9.3% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Absci's business is fine, but its cash and interest-bearing securities are about 57% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ABSI's ethical verdict changes
Today ABSI does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 17 Nov 2026: it trades at roughly a 49% discount to our $15.00 fair value.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. A 49.5% discount to the base estimate.
Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +98% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $15.00, with a range of $10.00 to $16.90, dated to the 2026-11-17 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsBiotech dreams meet collapsing revenue reality
Every new antibody therapy starts with a scientist in a lab hoping one molecule will tame disease where others failed. Absci is chasing that bet across inflammatory conditions, yet its revenue has fallen 82% while it posts zero profit margins and a negative 64% return on equity. The market prices the shares well below our calculated fair value, but the business shows none of the durable traits that justify stepping in.
Analyst notes highlight a strong buy chorus and a $13 target, and the name clears our ethical screen without flags. Still, a forward price to earnings ratio of negative 13 times and an unknown competitive moat leave the story resting on future clinical wins that remain unproven. We see no reason to override those numbers.
Clinical development carries binary trial outcomes and repeated cash calls that can wipe out early gains in months. Currency and sector swings add further volatility to an already fragile setup. Analysis, not advice.
| Forward P/E | -13.5x |
| EPS, trailing | -0.79 |
| EPS, forward | -0.69 |
| Revenue growth | -46.4%revenue is shrinking |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -57.7%not currently earning a positive return on equity |
| FCF yield | -3.14% |
| Debt to equity | 1.56a meaningful debt load worth watching |
| Current ratio | 10.63comfortably covers its short-term bills |
| Beta | 2.19much more volatile than the market |
| Short interest, float | 0.26% |
| 52-week range | 2.24 - 12.55 |
| Market cap | $1.6B |
| Employees | 140 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeABSI trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 7.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 73% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 73% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 73% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 66% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 66% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 10.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 66% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 5.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 66% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 66% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 5.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 67% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Absci (ABSI) Advances ABS 201 Plans, Is The 43% Discount Justified? Yahoo Finance · 4d ago
- Absci Corp (ABSI) Q3 2026 Earnings Call Highlights: ABS-201 Momentum Builds as Cash Runway ... Yahoo Finance · 5d ago
- Absci Corporation Q3 2026 Earnings Call Summary Yahoo Finance · 6d ago
- Absci (ABSI) Q3 2026 Earnings Call Transcript Yahoo Finance · 6d ago
- Absci Q3 Earnings Call Highlights Yahoo Finance · 6d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $5.78 | +15.7% | · | $1,157 | +15.7% |
| 2 months | $2.98 | +124.5% | · | $2,245 | +124.5% |
| 3 months | $2.30 | +190.9% | · | $2,909 | +190.9% |
| 6 months | $3.84 | +74.2% | · | $1,742 | +74.2% |
| 1 year | $3.03 | +120.8% | · | $2,208 | +120.8% |
| 2 years | $4.52 | +48.0% | · | $1,480 | +48.0% |
| 3 years | $1.68 | +298.2% | · | $3,982 | +298.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ABSI does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.